Pfm Health Sciences Q2 2026 Portfolio Activity: Strategic Shifts in Healthcare Stocks

PFM Health Sciences, Lp has released its portfolio activity data for the second quarter ending June 30, 2026. This comprehensive filing details changes to holdings across various sectors, providing valuable insight into the investment strategy of this fund.

Pfm Health Sciences' Q2 Purchases

This quarter saw PFM Health Sciences actively acquiring positions in several prominent Healthcare companies, signaling confidence in specific segments. Notable additions include:

• Humana Inc (HUM), where the fund increased its stake by a substantial 100%, adding shares worth $37.5 million to its portfolio.
• UnitedHealth Group Inc (UNH), seeing an increase of approximately 52% in holdings, equivalent to around 890,000 additional shares valued at $36.7 million.
• Icon PLC (ICLR), which experienced a significant buy of approximately 137% more shares than the previous quarter, adding roughly 79,000 shares worth $6.2 million.

These purchases suggest PFM Health Sciences is allocating capital towards large-cap Healthcare entities and potentially favoring segments related to health insurance and contract research services during this period.

Pfm Health Sciences' Q2 Sales and Reductions

In contrast, the fund also reduced or exited positions in several companies during Q2. The most significant reduction was observed in:

• Tenet Healthcare Corp (THC), where PFM Health Sciences sold off a large portion of its stake, reducing the position by approximately 68% or nearly 272,000 shares. This exit saw the stock value in the fund drop significantly.

Additionally, while not complete exits (as prior positions existed), there were substantial reductions that impacted portfolio allocation:

• Amneal Pharmaceuticals Inc (AMRX), experiencing a nearly 48% reduction in shares, equivalent to about 230,000 fewer shares valued at $5.6 million less.
• Compass Pathways PLC (CMPS), which saw its position drastically cut by over 81% or approximately one million fewer shares, significantly reducing the fund's exposure to this biotech holding.

These sales indicate a strategic shift away from certain Healthcare sectors or specific companies that may no longer align with PFM Health Sciences' investment thesis for Q2.

Pfm Health Sciences' Overall Portfolio Dynamics

The portfolio filing reveals high turnover, as changes were noted across 86 holdings during the quarter. The fund's primary sector allocation remains concentrated in Healthcare, which accounted for approximately $935 million or 94.9% of its total value ($985 million) as of June 30, 2026.

However, there are other sectors represented with smaller allocations:

• Syndax Pharmaceuticals Inc (SNDX), which experienced a significant reduction of over 51% in its position during the quarter.

The fund also appears to have maintained or slightly increased positions in some smaller Healthcare holdings, such as Arcutis Biotherapeutics Inc (ARQT) and Biacryst Pharmaceuticals Inc (BCRX), which saw their allocations increase to 0.55% and 0.18%, respectively.

Pfm Health Sciences' Investment Strategy Implications

The Q2 activity suggests PFM Health Sciences is actively managing its portfolio, prioritizing large-cap Healthcare stocks while strategically reducing exposure in others. The significant increase in the fund's holdings of Humana (HUM) and UnitedHealth (UNH), coupled with a major reduction in smaller biotechs like CMPS, points towards a preference for established players or specific segments within Healthcare.

The decision to exit positions in companies like THC and drastically reduce holdings such as AMRX and CMPS could be based on various factors including valuation concerns, strategic realignment, performance expectations, or regulatory developments affecting these firms. This dynamic approach highlights the fund's responsiveness to market conditions during the quarter.

Conclusion

Pfm Health Sciences demonstrated substantial activity in its Q2 2026 portfolio filing. The investment strategy involved significant purchases of large-cap Healthcare stocks like HUM, UNH, and ICLR, alongside major reductions or exits from positions in THC, AMRX, CMPS, and others.